Literature DB >> 10393885

Implications of immune-to-brain communication for sickness and pain.

L R Watkins1, S F Maier.   

Abstract

This review presents a view of hyperalgesia and allodynia not typical of the field as a whole. That is, exaggerated pain is presented as one of many natural consequences of peripheral infection and injury. The constellation of changes that results from such immune challenges is called the sickness response. This sickness response results from immune-to-brain communication initiated by proinflammatory cytokines released by activated immune cells. In response to signals it receives from the immune system, the brain orchestrates the broad array of physiological, behavioral, and hormonal changes that comprise the sickness response. The neurocircuitry and neurochemistry of sickness-induced hyperalgesia are described. One focus of this discussion is on the evidence that spinal cord microglia and astrocytes are key mediators of sickness-induced hyperalgesia. Last, evidence is presented that hyperalgesia and allodynia also result from direct immune activation, rather than neural activation, of these same spinal cord glia. Such glial activation is induced by viruses such as HIV-1 that are known to invade the central nervous system. Implications of exaggerated pain states created by peripheral and central immune activation are discussed.

Entities:  

Mesh:

Year:  1999        PMID: 10393885      PMCID: PMC33606          DOI: 10.1073/pnas.96.14.7710

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Cytokine expression in the brain during the acquired immunodeficiency syndrome.

Authors:  W R Tyor; J D Glass; J W Griffin; P S Becker; J C McArthur; L Bezman; D E Griffin
Journal:  Ann Neurol       Date:  1992-04       Impact factor: 10.422

Review 2.  Psychoneuroimmunology. The interface between behavior, brain, and immunity.

Authors:  S F Maier; L R Watkins; M Fleshner
Journal:  Am Psychol       Date:  1994-12

Review 3.  Cytokine-to-brain communication: a review & analysis of alternative mechanisms.

Authors:  L R Watkins; S F Maier; L E Goehler
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

4.  Characterization of a novel binding site for the human immunodeficiency virus type 1 envelope protein gp120 on human fetal astrocytes.

Authors:  M Ma; J D Geiger; A Nath
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

5.  Neurocircuitry of illness-induced hyperalgesia.

Authors:  L R Watkins; E P Wiertelak; L E Goehler; K Mooney-Heiberger; J Martinez; L Furness; K P Smith; S F Maier
Journal:  Brain Res       Date:  1994-03-14       Impact factor: 3.252

6.  Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin.

Authors:  S F Maier; E P Wiertelak; D Martin; L R Watkins
Journal:  Brain Res       Date:  1993-10-01       Impact factor: 3.252

7.  Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia.

Authors:  L R Watkins; L E Goehler; J Relton; M T Brewer; S F Maier
Journal:  Brain Res       Date:  1995-09-18       Impact factor: 3.252

8.  Characterization of cytokine-induced hyperalgesia.

Authors:  L R Watkins; E P Wiertelak; L E Goehler; K P Smith; D Martin; S F Maier
Journal:  Brain Res       Date:  1994-08-15       Impact factor: 3.252

9.  Production of interleukin-1 by microglia in response to substance P: role for a non-classical NK-1 receptor.

Authors:  F C Martin; P A Anton; J A Gornbein; F Shanahan; J E Merrill
Journal:  J Neuroimmunol       Date:  1993-01       Impact factor: 3.478

10.  Subcutaneous formalin produces centrifugal hyperalgesia at a non-injected site via the NMDA-nitric oxide cascade.

Authors:  E P Wiertelak; L E Furness; R Horan; J Martinez; S F Maier; L R Watkins
Journal:  Brain Res       Date:  1994-06-27       Impact factor: 3.252

View more
  53 in total

Review 1.  The neurobiology of pain.

Authors:  R Dubner; M Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 2.  Depression in medical illness: the role of the immune system.

Authors:  R Yirmiya
Journal:  West J Med       Date:  2000-11

Review 3.  Recent developments: management of pain.

Authors:  Anita Holdcroft; Ian Power
Journal:  BMJ       Date:  2003-03-22

4.  Fos expression in the rat brain after intraperitoneal injection of Staphylococcus enterotoxin B and the effect of vagotomy.

Authors:  Xi Wang; Bai-Ren Wang; Xi-Jing Zhang; Xiao-Li Duan; Xiang Guo; Gong Ju
Journal:  Neurochem Res       Date:  2004-09       Impact factor: 3.996

Review 5.  Rethinking inflammation: neural circuits in the regulation of immunity.

Authors:  Peder S Olofsson; Mauricio Rosas-Ballina; Yaakov A Levine; Kevin J Tracey
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

6.  Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.

Authors:  Felipe F Rodrigues; Marcela I Morais; Ivo S F Melo; Paulo S A Augusto; Marcela M G B Dutra; Sarah O A M Costa; Fábio C Costa; Franciele A Goulart; Alysson V Braga; Márcio M Coelho; Renes R Machado
Journal:  Inflammopharmacology       Date:  2019-11-25       Impact factor: 4.473

7.  Symptom clusters: establishing the link between clinical practice and symptom management research.

Authors:  Christine Miaskowski
Journal:  Support Care Cancer       Date:  2006-03-25       Impact factor: 3.603

Review 8.  Tissue pathophysiology, neuroplasticity and motor behavioural changes in painful repetitive motion injuries.

Authors:  Ann E Barr
Journal:  Man Ther       Date:  2006-05-23

9.  Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons.

Authors:  S B Oh; P B Tran; S E Gillard; R W Hurley; D L Hammond; R J Miller
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

Review 10.  Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens.

Authors:  Esther M Sternberg
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.